The application of exosomes as a nanoscale cancer vaccine

Abstract: Cancer is a leading cause of death globally, and it is predicted and projected to continue rising as life expectancy increases. Although patient survival rates for some forms of cancers are high due to clinical advances in treatment protocols, the search for effective cancer vaccines remains the ultimate Rosetta Stone in oncology. Cervarix®, Gardasil®, and hepatitis B vaccines are currently employed in preventing certain forms of viral cancers. However, they are, strictly speaking, not ‘true’ cancer vaccines as they are prophylactic rather than therapeutic, are only effective against the oncogenic viruses, and do not kill the actual cancer cells. On April 2010, a new prostate cancer vaccine Provenge® (sipuleucel-T) was approved by the US FDA, and it is the first approved therapeutic vaccine that utilizes antigen-presenting cell technology involving dendritic cells in cancer immunotherapy. Recent evidence suggests that the use of nanoscale particles like exosomes in immunotherapy could form a viable basis for the development of novel cancer vaccines, via antigen-presenting cell technology involving dendritic cells in cancer immunotherapy. Here, we review the current knowledge pertaining to exosome technology in immunotherapy and also seek to address the challenges and future directions associated with it, in hopes of bringing this exciting application a step closer toward an effective clinical reality.

Keywords: exosomes, cancer vaccine, immunotherapy, nanomedicine

Introduction
Cancer is a major global cause of morbidity and mortality, and it is expected to rise in the coming decades. Conventional treatments for cancer include the use of chemotherapeutic drugs, radiotherapy, and interventional surgery in the case of solid (and operable) tumors. Recent evidence suggests that the application of dendritic cell-derived exosomes (DEX), tumor cell-derived exosomes (TEX), and ascitic cell-derived exosomes (AEX) could emerge as novel nanoscale immunotherapy treatments for cancer, by priming the body’s immune system to recognize and kill cancer cells (Table 1).

Exosomes are nanoscale (50–100 nm) membrane vesicles, first described by Rose Johnstone in the 1970s, and it is postulated that they are involved in cell–cell communication, although its exact biological function and mechanism has, to this day, yet to be fully elucidated. The canonical exosome is of intracellular origin and displays MHC class I and II. It has also been shown to contain heat shock proteins and has a lipid composition rich in cholesterol, sphingomyelin, and ceramide. Its main protein markers are tetraspanins (CD63, CD9), Alix, and TSG101 and is able to mediate a
<table>
<thead>
<tr>
<th>Exosome type</th>
<th>Cancer type</th>
<th>Exosome purification</th>
<th>Exosome derivation and delivery</th>
<th>Results overview</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>DEX</td>
<td>Melanoma</td>
<td>Centrifugation up to 100,000 g 30% sucrose/D2O cushion Treatment with PBS</td>
<td>Exosomal MHC–peptide complex pulsed with melanoma antigen CTL pulsed with melanoma-primed-exosomes</td>
<td>DC release exosomes to other naive DC for T-cell priming Exosomes require mature DC to promote differentiation of melanoma-specific effector T cell producing IFN-γ effector lymphocytes T cell require mature DC to promote differentiation of melanoma-specific effector T cell producing IFN-γ effector lymphocytes</td>
<td>47</td>
</tr>
<tr>
<td>AEX</td>
<td>Various</td>
<td>Centrifugation up to 100,000 g 30% sucrose/D2O cushion Treatment with PBS</td>
<td>DC pulsed with AEX PBL stimulated with AEX-pulsed DC</td>
<td>Release of IFN-γ by PBL Tumor cell lysis</td>
<td>35</td>
</tr>
<tr>
<td>DEX</td>
<td>Toxoplasma gondii</td>
<td>Centrifugation up to 100,000 g Treatment with PBS</td>
<td>DEX pulsed with T. gondi-derived antigen</td>
<td>Murine models’ resistant brain cyst formation normally caused by T. gondii Production of T. gondii-specific antibody Increased production of cytokines Inhibition of tumor growth CTL-induced lysis of cancer cells</td>
<td>48</td>
</tr>
<tr>
<td>TEX</td>
<td>Leukemia</td>
<td>Centrifugation up to 100,000 g 30% sucrose/D2O cushion Treatment with PBS</td>
<td>Direct vaccination of murine models with TEX¹</td>
<td>Heat-shocked TEX more efficacious than TEX alone Immune response mostly mediated by CTL Upregulation of T₁,₁-mediated tumor response</td>
<td>34</td>
</tr>
<tr>
<td>DEX</td>
<td>Melanoma</td>
<td>Centrifugation up to 100,000 g 30% sucrose/D2O cushion Treatment with PBS</td>
<td>Exosomal MHC–peptide complex pulsed with melanoma antigen CTL pulsed with melanoma-primed exosomes + CpG adjuvants</td>
<td>CpG adjuvants + exosome elicit immune response toward cancer cells</td>
<td>62</td>
</tr>
<tr>
<td>TEX</td>
<td>Lymphoma</td>
<td>Centrifugation up to 100,000 g Treatment with PBS</td>
<td>Direct vaccination of murine models with TEX and heat-shocked TEX¹</td>
<td>Heat-shocked TEX more efficacious than TEX alone Immune response mostly mediated by CTL</td>
<td>60</td>
</tr>
<tr>
<td>TEX</td>
<td>Leukemia colon</td>
<td>Centrifugation up to 100,000 g Treatment with PBS</td>
<td>DC pulsed with heat-shocked TEX</td>
<td>Heat-shocked TEX more efficacious than TEX alone Immune response mostly mediated by CTL</td>
<td>38</td>
</tr>
<tr>
<td>TEX</td>
<td>Colon</td>
<td>Centrifugation up to 100,000 g Sucrose gradient Treatment with PBS</td>
<td>Human cancer antigen transfected onto murine TEX</td>
<td>Stimulation of immune cells Suppression of tumor growth</td>
<td>36</td>
</tr>
<tr>
<td>TEX</td>
<td>Colon</td>
<td>Centrifugation up to 100,000 g Sucrose gradient Treatment with PBS</td>
<td>Direct vaccination of murine models with TEX and heat-shocked TEX¹</td>
<td>Heat-shocked TEX more efficacious than TEX alone Immune response mostly mediated by CTL</td>
<td>60</td>
</tr>
<tr>
<td>TEX</td>
<td>CEA-expressing cells</td>
<td>Centrifugation up to 100,000 g 30% sucrose cushion Treatment with PBS</td>
<td>DC pulsed with cancer cell antigen Purified exosomes used with cyclo-phosphamide + polynosinic-polycytidylic acid</td>
<td>Heat-shocked TEX more efficacious than TEX alone Immune response mostly mediated by CTL</td>
<td>49</td>
</tr>
<tr>
<td>DEX</td>
<td>Leukemia</td>
<td>Centrifugation up to 100,000 g Treatment with PBS</td>
<td>DC pulsed with cancer cell to obtain DEX TEX obtained directly from cancer cells</td>
<td>DEX elicits a greater CTL anti-tumor response</td>
<td>50</td>
</tr>
<tr>
<td>DEX and TEX</td>
<td>Lung</td>
<td>Centrifugation up to 100,000 g Treatment with PBS</td>
<td>DC pulsed with cancer cells</td>
<td>CTL proliferation Eradication of established tumors Long-term CTL memory</td>
<td>51</td>
</tr>
<tr>
<td>DEX</td>
<td>Lung</td>
<td>Centrifugation up to 100,000 g Treatment with PBS</td>
<td>DC pulsed with cancer cells</td>
<td>CTL proliferation Eradication of established tumors Long-term CTL memory</td>
<td>51</td>
</tr>
<tr>
<td>DEX</td>
<td>Lung</td>
<td>Centrifugation up to 100,000 g Treatment with PBS</td>
<td>DC pulsed with cancer cells</td>
<td>CTL proliferation Eradication of established tumors Long-term CTL memory</td>
<td>51</td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>Exosome type</th>
<th>Cancer type</th>
<th>Exosome purification and delivery</th>
<th>Results overview</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DEX</strong></td>
<td>Mesothelioma</td>
<td>Centrifugation up to 100,000 g Treatment with PBS</td>
<td>DC pulsed with tumor cell line lysate</td>
<td>Antitumor immunity with prolonged murine model survival Resistance of secondary tumor challenge</td>
</tr>
<tr>
<td>TEX</td>
<td>Pancreatic</td>
<td>Centrifugation up to 200,000 g Treatment with PBS</td>
<td>Interaction of exosomal nanoparticles with pancreatic cancer cells induces apoptosis</td>
<td>Induction of apoptosis in cancer cells via notch signaling</td>
</tr>
<tr>
<td>TEX</td>
<td>Pancreatic</td>
<td>Centrifugation up to 200,000 g Treatment with PBS</td>
<td>Interaction of exosomal nanoparticles with pancreatic cancer cells induces apoptosis</td>
<td>Induction of apoptosis in cancer cells via Pi3K/Akt/GSK-3β survival pathway</td>
</tr>
<tr>
<td><strong>DEX</strong></td>
<td>Melanoma</td>
<td>Centrifugation up to 100,000 g Treatment with PBS</td>
<td>DC pulsed with cancer cells Addition of cyclo-phosphamide</td>
<td>Antigen-dependent antitumor effects against pre-existing tumors via CD4+ and CD8+ T cells</td>
</tr>
<tr>
<td>TEX</td>
<td>VSV</td>
<td>Centrifugation Treatment with PBS</td>
<td>Incorporation of VSV antigen onto exosome DC pulsed with VSV–exosome complex</td>
<td>Increased IgG antibody response Expansions of CTL Protection from challenge with ovalbumin expressing tumor cells</td>
</tr>
<tr>
<td><strong>DEX</strong></td>
<td>Melanoma</td>
<td>Centrifugation up to 100,000 g 30% sucrose/D2O cushion Treatment with PBS</td>
<td>DC pulsed with cancer cells</td>
<td>IL-15Rα-dependent cell proliferation NKG2D-dependent NK cell activation</td>
</tr>
<tr>
<td>TEX</td>
<td>Mesothelioma</td>
<td>Centrifugation up to 100,000 g Sucrose gradient Treatment with PBS</td>
<td>DC pulsed with TEX</td>
<td>Transfer of tumor antigen to DC Induction of CTL-dependent antitumor effect</td>
</tr>
<tr>
<td>TEX</td>
<td>Melanoma</td>
<td>Centrifugation up to 100,000 g Treatment with PBS</td>
<td>TEX engineered to display membrane-bound HSP70 DC pulsed with engineered TEX</td>
<td>CTL-mediated antitumor immunity NK cell-mediated antitumor immunity Membrane-bound HSP70 TEX more efficacious than cytoplasmic HSP70 TEX</td>
</tr>
<tr>
<td>TEX</td>
<td>Lymphoma</td>
<td>Centrifugation up to 100,000 g 30% sucrose cushion</td>
<td>TEX coated with SEA-TM domain Direct vaccination of modified TEx into murine models1</td>
<td>Inhibition of tumor growth Increased antigen-specific cytokine secretion by T cells SEA-TM-coated TEx elicits a more potent immune response</td>
</tr>
<tr>
<td>TEX</td>
<td>OVA-expressing tumor cells</td>
<td>Centrifugation up to 100,000 g 30% sucrose cushion</td>
<td>TEX with IL-2 genetic modification Direct vaccination of modified TEx into murine models1</td>
<td>Induction of antigen-specific T, I-polarized immune response Activation of CD4+ and CD8+ T cells Activation of NK cells IL-2 genetic modification elicits a more potent immune response</td>
</tr>
<tr>
<td>TEX</td>
<td>Fibrosarcoma OVA-expressing tumor cell lines</td>
<td>Centrifugation up to 100,000 g</td>
<td>Incorporation of tumor antigen onto TEx Direct vaccination of murine models1</td>
<td>More potent immune response toward vesicle-bound antigen than soluble antigen Mode of secretion can determine immunogenicity</td>
</tr>
<tr>
<td><strong>DEX</strong></td>
<td>Adenocarcinoma</td>
<td>Centrifugation up to 100,000 g Treatment with PBS</td>
<td>DC pulsed with tumor peptide Direct vaccination of murine models1</td>
<td>Priming of CTL Eradication and inhibition of established tumors</td>
</tr>
</tbody>
</table>

**Note:** In vivo study.

**Abbreviations:** PBS, phosphate-buffered saline; SEA-TM, enterotoxin A hydrophobic trans-membrane domain; CEA, carcinoembryonic antigen; DC, dendritic cell; CTL, cytotoxic T lymphocytes; PBL, peripheral blood leukocytes.
biological immune response by activating T lymphocytes (via antigen presentation), natural killer (NK) cells (via NKG2D ligand binding), and dendritic cells (via antigen transfer). The understanding of exosome biology has increased exponentially in recent years, leading to the creation of online databases such as Exocarta, an encyclopedia dedicated to providing original research findings about exosomes and their associated proteins.

The advent of nanotechnology has generated an immense interest among researchers in its application to medicine. A major goal of the utilization of nanoscale drug delivery systems is to improve its therapeutic index by increasing its potency at specific sites while simultaneously reducing systemic toxicity. Nanoscale drug delivery systems approved by the US Food and Drug Administration in cancer treatments are currently available, for example, Doxil® (doxorubicin encapsulated in liposomes) and Abraxane® (paclitaxel attached to nanoparticles). In addition to being novel drug delivery systems, nanoscale particles can also be specifically engineered to stimulate the immune system, which could form an attractive basis for cancer vaccine development.

There is increasing evidence that nanoscale particles, for example, recombinant virus-like particles (VLPs), inert nanobeads, and immunostimulating complexes, are being utilized in cancer vaccine development due to their effectiveness at eliciting cellular and humoral immune responses. It has been demonstrated that synthetic nanoparticles could be conjugated to biological molecules (eg, exosomes) and could potentially be used as an effective vaccine delivery system. Furthermore, there is a growing interest in the utilization of biological molecule delivery systems that serve as conduits to deliver genetic material, drug, or antigen into the body, and attractive candidates are liposomes, VLPs, erythrocyte ghosts, and exosomes (Figure 1).

Thus in this review, we seek to discuss the evidence pertaining to the use of exosomes as a cell-free (hence, conferring

Figure 1 Biological delivery systems. A) Bacteria can be used for gene delivery, and it is used in cancer gene therapy, DNA vaccination, and treatment of some genetic diseases. B) Bacteriophages are viruses that infect bacteria, and they can be genetically engineered and introduced into bacteria for genetic replication. C) Virus-like particles (VLPs) can be engineered from plasmids coding for viral structure proteins. These VLPs can then be linked to antigens and introduced into the body to elicit an immune response. D) Erythrocyte ghosts are red blood cells that have their cytoplasmic contents removed, and they can be used as vehicles for drug delivery. E) Exosomes are nanoscale vesicles released from dendritic cells and tumor cells, and they can be purified and loaded with antigens and introduced into the body to elicit a cell-specific anti-tumor response. Copyright © 2009, Nature Publishing Group. Reproduced with permission from Seow Y, Wood MJ. Biological gene delivery vehicles: beyond viral vectors. Mol Ther. 2009;17(5):767-777.
a low immunogenicity and high biosafety profile) nanoscale cancer vaccine and also to explore the potential of combining it with nanotechnology in the hopes of bringing the concept of immunotherapeutic cancer vaccines toward a viable and feasible clinical reality.

The search for a cancer vaccine
Significant clinical advances have been made in the treatment of cancer using the immune system. One of the best examples of this is the use of donor lymphocyte infusions, which is useful in treating chronic myeloid leukemia. Bone marrow transplantation has also revolutionized the way hematological malignancies are treated. However, the search for a true cancer vaccine remains largely elusive. Using cervical cancer as a prime example, current (prophylactic) treatment involves vaccination with either Cervarix® or Gardasil®, which are developed from and based on VLP technology, and is useful against cancer-causing variants of human papillomavirus (HPV). A modified strategy using long synthetic HPV oncopeptides has demonstrated that both CD8+ and CD4+ T-cell responses can be mounted in vivo and are capable of inducing complete remission in some patients with vulvar cancer. These results are very encouraging as, for the first time, an antiviral/tumor vaccine has successfully eradicated established tumors. However, these approaches are not ‘true’ cancer vaccines as an antiviral response is what kills the tumor. In the relentless pursuit of a true cancer vaccine, interesting approaches have been adopted by targeting ‘self’ proteins on cells that are only expressed at particular sites at specific time frames. Although these approaches have shown very promising results in murine models, their applicability to humans remain to be seen. In addition, the hepatitis B vaccine protects against hepatitis B virus, which is associated with liver cancer. Until recently, these so-called ‘cancer vaccines’ protect against viruses and are prophylactic (must be administered before the viral infection) rather than therapeutic because they do not kill the actual cancer cells.

On April 2010, the Food and Drug Administration approved the use of Provenge® (sipuleucel-T) in the treatment of advanced prostate cancer – the first ‘true’ therapeutic cancer vaccine that stimulates the body to kill cancer cells by eliciting a biological immune response. This involves pulsing dendritic cells with prostatic acid phosphatase-containing fusion protein in order to prime the immune system to recognize and kill prostate cancer cells. In terms of clinical trials in cancer vaccine development in the European Union and United States, this technique of pulsing dendritic cells with cancer antigen bears stark similarity with the clinical trials involving exosomes reviewed here, and therefore gives credence to the proof-of-concept that the application of exosome could be used as a nanoscale cancer vaccine.

Mounting evidence demonstrates that loading/pulsing dendritic cells with tumor antigens (or TEX) results in higher response rates in cancer patients in terms of eliciting an antitumor-specific immunity, compared to other types of vaccine formulations (eg, peptide vaccines and viral vector vaccines). This could well form a cornerstone by which cancer vaccines could be effectively developed in the future.

Cancer immunotherapy
For a cell to become cancerous, it must typically gain an oncogenic function (such as among many others, Myc, Bcl-2, and Ras, which promote cell proliferation), lose its tumor suppressor function (such as p53 and Rb, which promote cell arrest), and be immortalized. Within the tumor microenvironment, there is extensive interaction between cancer cells and immune cells, and cancer cells may escape immune surveillance by aberrant expression of antigen presentation (eg, lack of MHC I), absence of costimulatory molecules (eg, lack of B7 molecules), and release of immunosuppressive factors (eg, IL-10 and TGFβ). However, the ubiquitous question of why and how the immune system tolerates cancer cells in the first place remains poorly understood and has generated a relentless pursuit toward a search for an immunotherapeutic cancer vaccine.

Dendritic cells (or, more accurately, interdigitating dendritic cells) are professional antigen-presenting cells (APCs), which would be activated upon encountering a foreign agent and would interact with T cells to elicit an antigenspecific immune response. When immature dendritic cells are activated upon stimulation by foreign antigens, they become mature dendritic cells, which are powerful APCs, priming naïve lymphocytes as well as releasing chemokines to attract T cells (Figure 2). In contrast to using monoclonal antibodies in cancer immunotherapy, which is notorious for its systemic side effects like immunosuppression and hypersensitivity reactions due to by stander effects, dendritic cell-based immunotherapy could function as an attractive alternative for cancer treatment as the immune response mounted is more specific. Recent evidence shows that artificial APC systems are also emerging as powerful techniques for immunotherapy, and the superior biosafety profile of exosomes has made them an attractive candidate for cancer vaccine development.
Evidence for such a vaccine remains few and far between, an appropriate immune response toward cancer cells without a system to recognize specific tumor antigen and then mount an immune response. An ideal cancer vaccine should be able to prime the immune system to recognize specific tumor antigen and then mount an immune response toward cancer cells. Apart from stimulating the adaptive immune system by cross-priming cytotoxic T cells, it has also been shown that DEX suppresses tumor growth and also been shown that DEX suppresses tumor growth and also been shown that DEX suppresses tumor growth and also been shown that DEX suppresses tumor growth and also been shown that DEX suppresses tumor growth. Interestingly, induction of apoptosis in cancer cells via notch signaling and PI3K/Akt/GSK-3β survival pathways is observed when TEX interacts with pancreatic cancer cells. Apart from stimulating the adaptive immune system by cross-priming cytotoxic T cells, it has also been demonstrated that TEX can activate the innate immune system by increasing IgG antibody response and NK cells.

When dendritic cells are pulsed with cancer antigens or tumor peptides, DEX has been shown to elicit stronger immune responses toward cancer cells, with upregulation of specific antibody release and cytokine production. It has also been shown that DEX suppresses tumor growth and eradication of established tumors by CD8+ T cells and CD4+ T cells.
Application of exosomes as a nanoscale cancer vaccine

T cells, as well as breaking tolerance completely by resistance to secondary tumor challenge. Furthermore, it has also been reported that NK cells are involved in the immune response toward cancer cells via NKG2D-dependent NK cell activation and IL-15Rα-dependent cell proliferation. In terms of the mode of delivery, it has been shown that intradermal injection of DEX is more efficacious than subcutaneous, leading to suggestions that there might be more dendritic cells in the intradermal area than subcutaneous area.

To date, three Phase I clinical trials (China, France, and the United States) have been conducted, involving the application of exosomes to elicit immune responses against established tumors (Table 2). Dai et al reported that using AEX in patients with colorectal cancer induces

---

**Figure 3** Interactions of exosomes and other nanoscale vesicles with cells of the immune system. **A** A variety of cells secrete exosomes, and it can activate different types of immune cells, mainly via antigen presentation. **B**. Exosomes can also have an inhibitory effect on the immune system, although the mechanisms are not well understood. Copyright © 2009, Nature Publishing Group. Reproduced with permission from Thery C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. Nat Rev Immunol. 2009;9(8):581–593.
tumor antigen-specific cytotoxic T-cell responses, with none to minimal side effects, and is well tolerated by patients. Escudier et al.\(^5\) demonstrated the feasibility of scaling up and purification of clinical grade DEX using good manufacturing practice and restored the number and NKG2D-dependent function of NK cells in patients with melanoma (Figure 6).\(^5\) Furthermore, a study by Morse et al.\(^5\) indicates a MAGE-specific T cell response and increased NK lytic activity in patients with non-small cell lung carcinoma with the use of DEX.

**Challenges and future directions**

Although it has been established from the results in clinical trials that exosomes can be safely administered, their potency in terms of eliciting appropriate immune responses to kill cancer cells leaves much to be desired. The small number of patients involved in the clinical trials calls into question the statistical significance of the results. Most of the experimental evidence reviewed here revolves around solid tumors, and it has not been sufficiently demonstrated that non solid tumors (eg, hematological malignancies) can be treated using exosome technology. Furthermore, taking into account that exosomal immunotherapy relies heavily on the immune system, there remains a need to address the issue of cancer patients who are immunocompromised and/or immunosuppressed due to chemotherapy and radiotherapy regimens and therefore might not be able to sufficiently surmount cancer cells with their immune system alone.

Understandably, the next major goal is to increase the biological magnitude of the immune response, and this could be achieved perhaps by artificially coating and engineering exosomes\(^5\) with tumor antigens to make it more recognizable to the immune system. It has also been shown that heat-shocked TEX are more efficacious than TEX alone,\(^5\) as it confers a greater immunogenicity and elicits a greater immune response,\(^5\) thereby potentially making it a more effective cancer vaccine. It has also been shown that when CpG adjuvants are added alongside exosome therapy, naive T cells are more effectively primed.\(^5\)

The application and potential of nanotechnology in medicine heralds a beginning of a new chapter in the treatment of human diseases. Carbon nanotubes (CNTs) are allotropes of carbon, and research reveals that it not only has the potential for imaging and treating cancer cells, it can also be utilized in cancer vaccine delivery systems (Figure 7).\(^7\) There is evidence to suggest that CNTs, when conjugated to tumor antigens, elicits a specific antitumor response in animal models.\(^7\) Furthermore, it has been shown that peptide-functionalized CNTs can function as efficient vaccine delivery systems which trigger specific antibody responses.\(^5\) In addition, it has been experimentally demonstrated that ex vivo clonal expansion of T cells with antibody-linked CNTs results in T-cell activation and might prove to be a novel immunotherapy technique.\(^6\) There are currently no studies that explore the concept of combining CNTs with exosomes, and this could perhaps function as a novel technique for cancer vaccine delivery systems.
Development. Quantum dots (QDs) are also emerging as novel fluorescent probes for imaging and tracking the behavior of cells and nanoscale particles.67 QDs are semiconductor nanocrystals of about 2–10 nm capable of fluorescing at a greater intensity and are more photostable than conventional chromophores.68 Considering that exosomes are nanoscale spherical objects, it might also be possible to encapsulate or tether QDs with exosomes in order to image and track their progress in killing cancer cells.69 Theoretically, it might also be possible to engineer QDs to fluoresce at different colors to indicate different biological events, and this could be useful in monitoring the interactions of exosomes with T cells, NK cells, and dendritic cells in order to better understand its antitumor mechanism.70 Indeed, it has been experimentally demonstrated that using nanotechnology, exosomes can be engineered to bear an optimal number of MHC I and ligands that would activate T cells, and its in vivo activity can be traced by encapsulating superparamagnetic iron oxide nanoparticles (Figure 8).71 Exosomes can also carry cytokines, DNA, RNA, adjuvants, labels, costimulatory signals, and gene therapy vectors, which makes it the ultimate Trojan horse. Therefore, engineering the production of exosomes using nanotechnology embodies what we believe is the new platform for cancer vaccines of the future.

<table>
<thead>
<tr>
<th>Cancer type</th>
<th>No. of patients</th>
<th>Exosome type</th>
<th>Results</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colorectal</td>
<td>54</td>
<td>AEX</td>
<td>Detection of DTH</td>
<td>56</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Induction of tumor-specific antitumor CTL response</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>AEX + GM-CSF shows higher efficacy</td>
<td></td>
</tr>
<tr>
<td>Melanoma</td>
<td>15</td>
<td>DEX</td>
<td>Demonstrated feasibility of large-scale GMP exosome production</td>
<td>57, 54</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Well tolerated in patients with no major toxicity</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Restoration of number and NKG2D-dependent function of NK cells</td>
<td></td>
</tr>
<tr>
<td>NSCLC</td>
<td>13</td>
<td>DEX</td>
<td>Demonstrated feasibility of large-scale exosome production</td>
<td>58</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Well tolerated in patients with no major toxicity</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Stability of disease and activation of immune effectors</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: CTL, cytotoxic T lymphocytes; GM-CSF, granulocyte-macrophage colony-stimulating factor.
**Conclusion**

The application of immunotherapy represents a new paradigm in cancer treatment development. The utilization of exosomes in APC systems involving dendritic cells are emerging as powerful tools to prime the immune system in order to recognize and suppress cancer cell proliferation as well as eradicating established tumors. Despite the modest results of the Phase I clinical trials, the potential for and advancement of the application of exosomes as a nanoscale cancer vaccine are very real. Therefore, larger multicenter clinical trials are needed in order to establish the efficacy of exosomes, and more research has to be conducted to elucidate its mechanism of interaction with the immune system in order to improve its potency. Finally, coupling the use of exosomes with nanotechnology will most likely form the basis where novel nanoscale cancer vaccines will be developed in the future. Taken together, the current body of evidence indicate that exosomes could indeed be utilized as a novel nanoscale and cell-free cancer vaccine, and more research into this area is not only worth pursuing but paramount.

**Acknowledgment**

We would like to acknowledge the comments from Professor Jill Helms, University of Stanford.

**Disclosure**

The authors report no conflicts of interest in this work.

---

**Figure 8** Interaction of engineered exosomes with cells of the immune system. **A)** Engineered exosomes (red small circles) coated with A2*MHC class I molecules bound to CMV peptides do not bind CDB T cell (stained green) from a CMV positive donor who is HLA A2 negative, showing that exosomes do not bind randomly to T cells and that binding is very much MHC dependant. **B)** However, when the same exosomes carrying A2*MHC/CMV complexes are cocultured with T cell from a CMV+ and A2+ donor, direct interaction between exosomes and CDB T cells is clearly seen. **C)** Engineered exosomes (stained red) also bind to natural APCs (stained green and orange when the red and green color overlaps). This figure shows a natural APC activating three different CD8 T cells via engineered exosomes. **D)** Exosomes bind to APC naturally whether they are engineered or not as the lipids themselves are the binding sites. Copyright © 2009, Nature Publishing Group.

**References**


